Jacob Kimmel

In this enlightening conversation, Jacob Kimmel, Co-founder and President of NewLimit, shares his groundbreaking work in reversing aging through epigenetic reprogramming. He discusses why evolution hasn't optimized for longevity and the complexities of drug discovery. The chat delves into the role of transcription factors in rejuvenating cells and innovative gene delivery methods that could transform medical treatments. Kimmel also offers intriguing insights into CAR-T cell therapy and how biotech innovations may revolutionize healthcare.

Jacob Kimmel, co-founder and president of New Limit, shares insights into revolutionary biotech aimed at reprogramming cellular aging. He discusses their groundbreaking work with transcription factors, which can potentially restore youthful cell functions. Exciting advancements in epigenetic reprogramming are revealed, including successes in rejuvenating old liver cells. Kimmel emphasizes the collaboration between academia and industry driving progress in longevity science, and the challenges faced in gene manipulation as they seek to enhance human health and lifespan.

In this engaging discussion, Jacob Kimmel, co-founder of NewLimit, explores the frontier of biotechnology to reverse aging. He defines aging as loss of function linked to evolutionary pressures and introduces epigenetic reprogramming as a game-changing approach. Kimmel highlights the importance of data-driven models in predictive biology and discusses how NewLimit's innovative therapies aim to rejuvenate cells. He also emphasizes achievable longevity goals while warning against extreme lifespan fantasies, making a compelling case for the science of aging.

Jacob Kimmel, co-founder and president of New Limit, dives into the revolutionary world of longevity medicine, exploring the future of epigenetic reprogramming and its potential to enhance health and lifespan. Sam Lessin of Slow Ventures shares insights on OpenAI's competitive hiring platform, discussing the evolving skills needed in entrepreneurship and the tech landscape. The conversation also touches on the rising popularity of GLP-1 medications in Silicon Valley, highlighting not just weight loss benefits but broader lifestyle impacts, all set against the backdrop of the shifting enterprise software market.

Join Jacob Kimmel, co-founder of New Limit, as he discusses revolutionary approaches to extending human lifespan through epigenetic reprogramming. Santi Ruiz from the Institute for Progress shares insights on the intersection of innovation policy and nonprofit challenges in tech. Kelvin Yu explores the dynamics of Silicon Valley's tech culture, while Jim Blum sheds light on advancements in shipbuilding. Fil Aronshtein navigates the complexities of AI and Hollywood, sparking a lively conversation about the future of both industries.